DETAILED ACTION
Election/Restrictions
Applicant’s election without traverse of selected species in the reply filed on August 18, 2026 is acknowledged. The elected species are: Shiga toxin, Cathepsin L cleavage site, SEQ ID NO: 14, 19, N protein, D14G, S68F, I82T, R203K and anti-PD-L1 antibody. Claims 4, 5, 10, 12 are withdrawn from consideration being directed to non-elected species.
Claims Summary
Claim 1 is directed to a fusion protein comprising:
A CD40-binding domain which is a CD40 ligand (CD40L) or a functional fragment thereof comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 19; SEQ ID NO: 19 is 154-aa and represents a truncated CD40L ligand, CD40L108-261, also termed 18sCD40L; the CD40L or functional fragment thereof consists of 154-261 amino acid residues in length; the CD40 ligand or functional fragment thereof comprises SEQ ID NO: 19 and is 154-261 amino acids in length (claim 7); the CD40 ligand consists of 143-261 amino acids and comprises an amino acid sequence that is at least 97% identical to SEQ ID NO: 19 (claim 8);
A nucleocapsid (N) antigen of SARS-CoV-2 (elected species, claim 1 and all dependent claims, including claims 18 and 19); the SARS-CoV-2 is a Wuhan-Hu-1 strain with a NCBI reference number NC_045512.2, or a viral variant thereof (claim 9); the antigen comprises 8-491 amino acids selected from a region of SEQ ID NO: 46 of the N protein, optionally/comprising a mutation R203K (claims 11 and 13);
A translocation domain comprising a Shiga toxin (Stx) translocation peptide, located between the CD40-binding domain and the antigen; the antigen is located at the N-terminal of the fusion protein (claim 20); the Stx peptide consisting of 8-84 amino acid residues in length and comprises SEQ ID NO: 14 (claim 2) or is at least 95% identical to SEQ ID NO: 14 (claim 3); SEQ ID NO: 14 is 37-aa and represents Stx211-247; and,
A cathepsin L cleavage site (elected species), located immediately adjacent to the CL40-binding domain and the translocation domain; the cathepsin L cleavage site comprises an amino acid sequence of RX1X2R or RX1X2X3, wherein X1 and X2 are any amino acid residue, and X3 is K, F or R (claim 6);
Also claimed is a pharmaceutical composition comprising a fusion protein of claim 1 and a pharmaceutical acceptable carrier and/or an adjuvant (claim 14), and further comprising an immune checkpoint antibody that can activate a T cell (claim 16), specifically an anti-PD-L1 antibody (claim 17). Claim 15 is directed to a method for eliciting an antigen-specific, cell-mediated immune response against SARS-CoV-2 infection, and/or for reducing, inhibiting, treating, and ameliorating symptoms caused by SARS-CoV-2 infection, comprising administering a therapeutically effective amount of a fusion protein of claim to a subject in need thereof.
Claim Objections
Claim 15 is objected to because of the following informality:
Claim 15, line 6, there is a space between “t” and “hereof”.
Appropriate correction is required.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1-3, 6-9, 11 and 13-20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Regarding the functional fragment of CD40L, SEQ ID NO: 19, in claim 1, the recited lower limit of the length of the fragment is 154-aa. However, SEQ ID NO: 19 is 154-aa in length. It would appear that the fragment is not shorter than SEQ ID NO: 19. Correction and/or clarification is required. Dependent claims 2, 3, 6-9, 11 and 13-20 are included in this rejection.
Claim 9 is directed and embodiment wherein the SARS-CoV-2 is a Wuhan-Hu-1 strain with a NCBI reference number NC_045512.2, or a viral variant thereof. Regarding the recitation of NCBI reference number NC_045512.2, this reference to a Genbank accession number rather than to specific sequences identified by SEQ ID NO, is seen as an improper incorporation by reference, since the information required to describe and enable the required sequences is found in the Genbank database, extraneous to the application. Furthermore, since Genbank sequences are not irrevocably fixed but are corrected and updated as additional sequence information becomes available. The Genbank accession number may refer to sequences which change after the application filing date. Since GenBank entries may change, there is no indication that any given sequence therein would correspond to a specific sequence that applicant intends to claim in an application. For these reasons, it is unclear which structures are intended to be encompassed by the instant sequences referred to in the claims. It follows that the metes and bounds of viral variants of a Wuhan-Hu-1 strain with a NCBI reference number NC_045512.2 cannot be determined. Even if the base sequence for the Wuhan-Hu-1 strain is identified by a sequence identifier (SEQ ID NO), the specification does not provide a definition of the “viral variant” such that the metes and bounds could be determined. It is not clear what structures would qualify as variants.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-3, 6-8, 14, 15 and 18-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-6, 8-18 and 20 of U.S. Patent No. 12,358,996 B2 in view of Niazi et al. (US 2021/0284713 A1, “Niazi”). The patented claims are directed to a fusion protein comprising a CD40L or a functional fragment thereof comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 19, consisting of 154-261 amino acids in length, an antigen of a pathogen, such as an antigen from SARS-CoV2 (copending claim 8) located at the N-terminus of the fusion protein, an Stx translocation domain, a cathepsin L cleavage site located between the CD40L and the Stx. Other limitations of sequences, linkers and methods of eliciting an immune response are in patented claims 2-6, 9-18 and 20.
The patented claims do not specify that the antigen from the N protein of a SARS-CoV2 virus. However, it would have been obvious to have claimed such. Niazi discloses a fusion protein comprising CD40L extracellular portion coupled by a flexible linker to a SARS-CoV-2 N protein as anti-COVID-19 therapy. Given that the patented claims are broadly directed to an antigen from SARS-CoV-2, it would have been obvious to have claimed an antigen from the N protein, specifically, with a reasonable expectation of success. Niazi also discloses pharmaceutical compositions and pharmaceutically acceptable carriers (see paragraph [0073]). It would have been obvious to have formulated the patented fusion protein in a pharmaceutical composition with a carrier since the fusion protein is used in methods of inducing an immune response, with a reasonable expectation of success.
Claims 1, 6-8, 14, 15, 18 and 19 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 2, 7, 17, 19, 27, 30-31 and 34-39 of copending Application No. 17/240,160 in view of Niazi et al. (US 2021/0284713 A1, “Niazi”).
The copending claims are directed to a fusion protein comprising a CD40L or a functional fragment thereof comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 19, consisting of 154-261 amino acids in length and located at the N-terminus of the fusion protein; an antigen of a pathogen, such as an antigen from SARS-CoV2 (copending claims 14 and 33) located at the C-terminus of the fusion protein; a PE translocation peptide; a cathepsin L cleavage site located immediately adjacent to the CD40L and the PE translocation peptide. Other limitations of sequences, linkers and methods of eliciting an immune response are in copending claims 2, 7, 19, 31, 36 and 38. Although the embodiment of the PE translocation domain is not the elected species in this application at present, it is included in this rejection since it is recited in claims that are under examination.
The copending claims do not specify that the antigen from the N protein of a SARS-CoV2 virus. However, it would have been obvious to have claimed such. Niazi discloses a fusion protein comprising CD40L extracellular portion coupled by a flexible linker to a SARS-CoV-2 N protein as anti-COVID-19 therapy. Given that the copending claims are broadly directed to an antigen from SARS-CoV-2, it would have been obvious to have claimed an antigen from the N protein, specifically, with a reasonable expectation of success. Niazi also discloses pharmaceutical compositions and pharmaceutically acceptable carriers (see paragraph [0073]). It would have been obvious to have formulated the copending claims’ fusion protein in a pharmaceutical composition with a carrier since the fusion protein is used in methods of inducing an immune response, with a reasonable expectation of success. This is a provisional nonstatutory double patenting rejection.
Claims 1-3, 6-8 and 14-20 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-8, 10 and 12-20 of copending Application No. 18/697,859 in view of Niazi et al. (US 2021/0284713 A1, “Niazi”).
The copending claims are directed to a combination comprising an immune checkpoint antibody capable of activating a T-cell, such as anti-PD-L1 antibody (copending claim 14), the fusion protein comprising a CD40L or a functional fragment thereof comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 19, consisting of 154-261 amino acids in length; an antigen of a pathogen, such as an antigen from SARS-CoV2 (copending claim 12) located at the N-terminus of the fusion protein if the translocation peptide is Stx, or at the C-terminus if the translocation peptide is PE; an Stx or PE translocation peptide; a cathepsin L cleavage site located between the CD40L and the PE translocation peptide. Other limitations of sequences, linkers and methods of eliciting an immune response are in copending claims 2-5, 7, 8 and 17-20. Although the embodiment of the PE translocation domain is not the elected species in this application at present, it is included in this rejection since it is recited in claims that are under examination.
The copending claims do not specify that the antigen from the N protein of a SARS-CoV2 virus. However, it would have been obvious to have claimed such. Niazi discloses a fusion protein comprising CD40L extracellular portion coupled by a flexible linker to a SARS-CoV-2 N protein as anti-COVID-19 therapy. Given that the copending claims are broadly directed to an antigen from SARS-CoV-2, it would have been obvious to have claimed an antigen from the N protein, specifically, with a reasonable expectation of success. Niazi also discloses pharmaceutical compositions and pharmaceutically acceptable carriers (see paragraph [0073]). It would have been obvious to have formulated the copending claims’ fusion protein in a pharmaceutical composition with a carrier since the fusion protein is used in methods of inducing an immune response, with a reasonable expectation of success. This is a provisional nonstatutory double patenting rejection.
Conclusion
No claim is allowed.
The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Niazi et al. (US 2021/0284713 A1, “Niazi”) discloses a fusion protein comprising CD40L extracellular portion coupled by a flexible linker to a SARS-CoV-2 N protein. However, there is no teaching or fair suggestion to include a translocation domain or a cathepsin L cleavage site in Niazi’s fusion protein.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stacy B. Chen whose telephone number is 571-272-0896. The examiner can normally be reached on M-F (7:00-4:30). If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Thomas Visone, can be reached on 571-270-0684. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
/STACY B CHEN/Primary Examiner, Art Unit 1672